Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Duerinck J, Du Four S, Bouttens F, Andre C, Verschaeve V, Van Fraeyenhove F, Chaskis C, D'Haene N, Le Mercier M, Rogiers A, Michotte A, Salmon I, Neyns B. Duerinck J, et al. Among authors: rogiers a. J Neurooncol. 2018 Jan;136(1):115-125. doi: 10.1007/s11060-017-2629-z. Epub 2017 Oct 7. J Neurooncol. 2018. PMID: 28988341 Clinical Trial.
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab.
Rogiers A, Leys C, Lauwyck J, Schembri A, Awada G, Schwarze JK, De Cremer J, Theuns P, Maruff P, De Ridder M, Bernheim JL, Neyns B. Rogiers A, et al. J Immunol Res. 2020 Jul 21;2020:2192480. doi: 10.1155/2020/2192480. eCollection 2020. J Immunol Res. 2020. PMID: 32775464 Free PMC article. Clinical Trial.
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).
Awada G, Ben Salama L, De Cremer J, Schwarze JK, Fischbuch L, Seynaeve L, Du Four S, Vanbinst AM, Michotte A, Everaert H, Rogiers A, Theuns P, Duerinck J, Neyns B. Awada G, et al. Among authors: rogiers a. J Immunother Cancer. 2020 Oct;8(2):e001146. doi: 10.1136/jitc-2020-001146. J Immunother Cancer. 2020. PMID: 33067319 Free PMC article. Clinical Trial.
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.
Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. Awada G, et al. Among authors: rogiers a. Cancers (Basel). 2021 Jan 6;13(2):168. doi: 10.3390/cancers13020168. Cancers (Basel). 2021. PMID: 33418936 Free PMC article.
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.
Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK, Pappot H, Aspeslagh S, Rogiers A, Neyns B, Haanen JB, Mitchell SA, Addeo A, Michielin O, Eicher M. Da Silva Lopes AM, et al. Among authors: rogiers a. Eur J Cancer. 2021 Nov;157:225-237. doi: 10.1016/j.ejca.2021.08.026. Epub 2021 Sep 15. Eur J Cancer. 2021. PMID: 34536946 Free article.
Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Neyns B, Janssen KJ, Blank CU, Retèl VP, Boekhout AH. Egeler MD, et al. Among authors: rogiers a. Qual Life Res. 2023 Sep;32(9):2517-2525. doi: 10.1007/s11136-023-03427-9. Epub 2023 Apr 20. Qual Life Res. 2023. PMID: 37079262
49 results